Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland

Large-scale sequencing studies are rapidly identifying putative oncogenic mutations in human tumors. However, discrimination between passenger and driver events in tumorigenesis remains challenging and requires in vivo validation studies in reliable animal models of human cancer. In this study, we describe a novel strategy for in vivo validation of candidate tumor suppressors implicated in invasive lobular breast carcinoma (ILC), which is hallmarked by loss of the cell-cell adhesion molecule E-cadherin. We describe an approach to model ILC by intraductal injection of lentiviral vectors encoding Cre recombinase, the CRISPR/Cas9 system, or both in female mice carrying conditional alleles of the Cdh1 gene, encoding for E-cadherin. Using this approach, we were able to target ILC-initiating cells and induce specific gene disruption of Pten by CRISPR/Cas9-mediated somatic gene editing. Whereas intraductal injection of Cas9-encoding lentiviruses induced Cas9-specific immune responses and development of tumors that did not resemble ILC, lentiviral delivery of a Pten targeting single-guide RNA (sgRNA) in mice with mammary gland-specific loss of E-cadherin and expression of Cas9 efficiently induced ILC development. This versatile platform can be used for rapid in vivo testing of putative tumor suppressor genes implicated in ILC, providing new opportunities for modeling invasive lobular breast carcinoma in mice.

[1]  J. Azzopardi,et al.  Invasive lobular carcinoma of the breast: incidence and variants , 1979, Histopathology.

[2]  M. Borst,et al.  Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. , 1993, Surgery.

[3]  M. J. van de Vijver,et al.  © 1997 Cancer Research Campaign , 2022 .

[4]  I. Ellis,et al.  Clinical and Biological Significance of E-cadherin Protein Expression in Invasive Lobular Carcinoma of the Breast , 2010, The American journal of surgical pathology.

[5]  W. Birchmeier,et al.  Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. , 1993, The American journal of pathology.

[6]  L. Ailles,et al.  Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.

[7]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[8]  M. Taketo,et al.  Hepatocarcinogenesis in Mice with β-Catenin and Ha-Ras Gene Mutations , 2004, Cancer Research.

[9]  Zhiping Weng,et al.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.

[10]  M. Neville,et al.  Transduction of the Mammary Epithelium with Adenovirus Vectors In Vivo , 2003, Journal of Virology.

[11]  R. Kemler,et al.  E-cadherin is a survival factor for the lactating mouse mammary gland , 2002, Mechanisms of Development.

[12]  R. Roylance,et al.  Multiple ways of silencing E‐cadherin gene expression in lobular carcinoma of the breast , 2001, International journal of cancer.

[13]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[14]  Francisco J. Sánchez-Rivera,et al.  Rapid modeling of cooperating genetic events in cancer through somatic genome editing , 2014, Nature.

[15]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[16]  L. Hennighausen,et al.  Cre-mediated gene deletion in the mammary gland. , 1997, Nucleic acids research.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[18]  Zhe Li,et al.  Lineage Tracing of Mammary Epithelial Cells Using Cell-Type-Specific Cre-Expressing Adenoviruses , 2014, Stem cell reports.

[19]  Christopher M. Vockley,et al.  Epigenome editing by a CRISPR/Cas9-based acetyltransferase activates genes from promoters and enhancers , 2015, Nature Biotechnology.

[20]  S. Linn,et al.  Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene , 2001, Oncogene.

[21]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[22]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[23]  Mathias J Friedrich,et al.  CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice , 2015, Proceedings of the National Academy of Sciences.

[24]  Dian Yang,et al.  Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing , 2015, Genes & development.

[25]  C. Moskaluk,et al.  Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue. , 2011, Genes & development.

[26]  S. Fiering,et al.  Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer , 2014, Journal of visualized experiments : JoVE.

[27]  Andrew J Ewald,et al.  Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. , 2008, Developmental cell.

[28]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[29]  A. Berns,et al.  PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. , 2002, Development.

[30]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[31]  I. Huijbers,et al.  Using the GEMM-ESC strategy to study gene function in mouse models , 2015, Nature Protocols.

[32]  J. Jonkers,et al.  A preclinical mouse model of invasive lobular breast cancer metastasis. , 2013, Cancer research.

[33]  Hanns Lochmüller,et al.  High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. , 1998, Human gene therapy.

[34]  Jan Grimm,et al.  A spatially and temporally restricted mouse model of soft tissue sarcoma , 2007, Nature Medicine.

[35]  Jos Jonkers,et al.  Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. , 2006, Cancer cell.

[36]  I. Huijbers,et al.  Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer , 2015, Proceedings of the National Academy of Sciences.

[37]  D. Ingber,et al.  Intraductal Injection for Localized Drug Delivery to the Mouse Mammary Gland , 2013, Journal of visualized experiments : JoVE.

[38]  R. Epstein,et al.  Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy , 2014, BMC Cancer.

[39]  I. Huijbers,et al.  Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells , 2014, EMBO molecular medicine.

[40]  Hao Yin,et al.  CRISPR-mediated direct mutation of cancer genes in the mouse liver , 2014, Nature.

[41]  J. Wesseling,et al.  Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice , 2011, Disease Models & Mechanisms.

[42]  L. Luo,et al.  A global double‐fluorescent Cre reporter mouse , 2007, Genesis.

[43]  Volker Hovestadt,et al.  Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling , 2015, Nature Communications.